Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-arm, Single-center, Open-label, Prospective Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

NCT07462468 is registered in ClinicalTrials.gov with WestVac Biopharma Co., Ltd. as lead sponsor.

NCT NCT07462468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07462468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-arm, Single-center, Open-label, Prospective Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Lead sponsor
WestVac Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 10, 2026
Completion date
September 30, 2027
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant recurrent ovarian cancer (proc)